pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Updates
The latest update as of June 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows:
- Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations
- Seven negotiations have been completed since the last update, for a total of 160 joint negotiations.
- No new drug products were added to the “No pCPA Negotiations” list
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since May 30th, 2017 is:
- Three new drug products have received recent CDEC or pERC recommendations, for a total of approximately 24 products under pCPA Consideration
Please see below for more details.
- Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations
- Caprelsa (vandetanib; Sanofi-Genzyme) – Medullary thyroid cancer
- Kyprolis (Carfilzomib; Amgen Canada Inc.) – Multiple Myeloma (relapsed)
- Narcan (naloxone hydrochloride; Adapt Pharma) – Opioid overdose
- Otezla (Apremilast; Celgene) – Moderate to severe plaque psoriasis
- Revestive (Teduglutide; Shire Pharma Canada ULC/NPS Pharma Holdings Limited) – Short Bowel Syndrome (SBS)
- Strensiq (asfotase alfa, Alexion Pharmaceuticals Canada) – Pediatric onset hypophosphatasia
- Seven negotiations have been completed since the last update, for a total of 160 joint negotiations.
- Brenzys (etanercept; Merck Canada Inc.) – rheumatoid arthritis and ankylosing spondylitis
- Imbruvica (ibrutinib; Janssen Canada Inc.) – relapsed/refractory Mantle Cell Lymphoma
- Imbruvica (ibrutinib; Janssen Canada Inc.) – chronic lymphocytic leukemia and small lymphocytic lymphoma
- Lenvima (lenvatinib; Eisai Limited) – thyroid cancer
- Mozobil (plerixafor; Genzyme Canada Inc.) – granulocyte colony stimulating factor to support treatment for non-Hodgkin lymphoma and multiple myeloma (second letter of intent)
- Neupro (rotigotine; UCB Canada Inc.) – Parkinson’s Disease
- XigDuo (dapagliflozin/metformin hydrochloride: AstraZeneca Canada Inc.) – Type 2 diabetes mellitus
- No new drug products were added to the “No pCPA Negotiations” list
Based on information collected by MORSE Consulting:
- Three new drug products have received recent CDEC or pERC recommendations or notifications to implement since the last update, for a total of approximately 24 products under pCPA Consideration.
Please note; the date provided is the date of the Final Recommendation or Notification to Implement where applicable.
- Inlyta (axitinib; Pfizer Canada Inc.; June 30, 2017) – metastatic renal cell carcinoma
- Gazyva (obinutuzumab; Hoffman-la Roche Ltd.; June 19, 2017) – follicular lymphoma
- Zinbryta (daclizumab beta; Biogen Canada Inc.; June 20, 2017) – multiple sclerosis, relapsing
Deciphering this Signal
There are three products from the latest pCPA update that we believe are worthy of note:
- Brenzys – Completed its negotiations with the pCPA marking the second anti-TNF biosimilar product through the pCPA process.
- Narcan – pCPA has initiated a negotiation for a product that has not received a recommendation from CADTH.
- Strensiq – Has moved from the list of closed negotiations back to the active pCPA negotiation list.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
